Hybrid Plasma Markers that Complement CT Imaging for Early Lung Cancer Detection
混合血浆标记物可补充 CT 成像以进行早期肺癌检测
基本信息
- 批准号:9248994
- 负责人:
- 金额:$ 51.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-01 至 2020-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdherenceAgeAge-YearsAlgorithmsAntibodiesAntigensApoptosisAttentionAutoantibodiesB-LymphocytesBenignBiological MarkersBiopsyBloodBreastCancer EtiologyCancer HistologyCancerousCaringCellsCessation of lifeCharacteristicsChestChronic Obstructive Airway DiseaseClinicClinicalClinical DataColonColon CarcinomaComplementComplexCosts and BenefitsDataDetectionDiagnosisDiagnosticDimensionsDoseEnzyme-Linked Immunosorbent AssayEvaluationFDA approvedGenderGuidelinesHybridsImageImmuneImmunologic MarkersInfiltrationLungLung noduleMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of ovaryMedicalMetabolismMethodsModelingMorbidity - disease rateMultivariate AnalysisNoduleOperative Surgical ProceduresPancreasPatient CarePatientsPlasmaPractice GuidelinesProceduresPropertyProstateProtein ArrayProteomicsRaceRadiation exposureReportingReproducibilityResearch DesignRestRisk stratificationSamplingScanningSeveritiesSmokerSmoking HistorySpecificitySpecimenSurvival RateTestingTranslationsTumor-DerivedTumor-Infiltrating LymphocytesUnited StatesUnnecessary ProceduresValidationVariantX-Ray Computed Tomographyagedangiogenesisbasebiomarker discoverybiomarker panelblood-based biomarkercancer cellcancer diagnosiscandidate markercardiovascular healthcase controlchest computed tomographyclinical carecohortcostdensitydesignhigh riskhigh risk populationimprovedlung cancer screeninglung imagingmalignant breast neoplasmmortalitynew technologyoutcome forecastperformance testspredictive modelingprogramsprospectivepublic health relevancescreeningstandard caretheories
项目摘要
DESCRIPTION (provided by applicant): Lung cancer is the leading cause of cancer death in the United States and worldwide. In 2013, it is estimated that there will be at least 228,000 new cases of lung cancer diagnosed and more than 159,000 deaths in the United States - approximately equal to the next four most common causes of cancer-related mortality combined (colon, breast, prostate, pancreas). The NCI-sponsored, National Lung Screening Trial (NLST) found a 20% reduction in lung cancer specific mortality in high-risk subjects screened with low-dose chest computed tomography (CT). However, 26% of CT-scans reported noncalcified nodules >4 mm while only 5% of these positive findings would actually be expected to be cancer. Analysis of several screening cohorts indicates that 25-50% of smokers >50 years of age have CT identifiable pulmonary nodules but very few of them (~2.5%) are caused by lung cancer. Current practice guidelines for pulmonary nodule evaluation call for invasive biopsy procedures depending upon the size and characteristics of the nodule and key clinical parameters (e.g., age, smoking history), raising considerable cost/benefit and morbidity/mortality considerations even in this high-risk population. Clearly there is a need for additional risk stratification for subjects that have pulmonary nodules detected by CT imaging. Discovery of viable proteomic, glycomic and/or immunological biomarkers in blood to complement CT would be especially valuable to guide clinical care. However, no plasma markers have advanced sufficiently in validation trials to be viable FDA-approved candidates. We created a high density antibody array containing 3200 different antibodies that we use to interrogate pre-diagnostic sample sets from observational trials in a nested case-control design study to evaluate proteomic, glycomic and autoantibody differences. We have shown that this novel technology is highly sensitive and reproducible. Furthermore, we have confirmed known and found new viable proteomic biomarker candidates in ovarian, breast, colon and lung cancer. Using pre-diagnostic lung cancer samples from the Cardiovascular Health Study (CHS), we found 30 proteomic, glycomic or autoantibody biomarkers that were significantly increased (p<0.002) in people that are subsequently diagnosed with lung cancer. Here, we propose to use plasma samples from 297 lung nodule positive subjects that have been screened via CT and have known cancer/nodule status (147 were cancer) to test these 30 markers and potentially discover additional candidates. We will then combine these data with CT imaging parameters and clinical data to create a risk prediction model that we will test in a similar sized prospectivly collected cohort. Our specific aims are: (1) Test the ability of putative proteomic and glycomic biomarkers to identify malignant pulmonary nodules. (2) Determine if autoantibodies present in plasma are tumor-derived and assess their utility for the detection of cancerous nodules. (3) Perform multivariate analyses of hybrid plasma biomarkers to distinguish malignant from benign nodules identified on CT chest imaging.
描述(由申请人提供):肺癌是美国和全世界癌症死亡的主要原因。2013年,据估计,美国将有至少228,000例新的肺癌诊断病例和超过159,000例死亡-大约等于癌症相关死亡率的下四个最常见原因的总和(结肠癌,乳腺癌,前列腺癌,胰腺癌)。NCI赞助的国家肺筛查试验(NLST)发现,在接受低剂量胸部计算机断层扫描(CT)筛查的高危受试者中,肺癌特异性死亡率降低了20%。然而,26%的CT扫描报告了>4 mm的非钙化结节,而这些阳性结果中只有5%实际上被预期为癌症。对几个筛查队列的分析表明,25-50%的>50岁的吸烟者具有CT可识别的肺结节,但其中很少(约2.5%)是由肺癌引起的。肺结节评估的当前实践指南要求根据结节的大小和特征以及关键临床参数(例如,年龄、吸烟史),即使在这种高风险人群中也会引起相当大的成本/效益和发病率/死亡率考虑。显然,需要对CT成像检测到肺结节的受试者进行额外的风险分层。在血液中发现可行的蛋白质组学、糖组学和/或免疫学生物标志物以补充CT将对指导临床护理特别有价值。然而,没有血浆标记物在验证试验中得到足够的进展,成为FDA批准的可行候选物。我们创建了一个包含3200种不同抗体的高密度抗体阵列,用于在巢式病例对照设计研究中询问来自观察性试验的诊断前样本集,以评估蛋白质组学,糖组学和自身抗体差异。我们已经证明,这种新技术是高度敏感和可重复的。此外,我们已经证实了已知的和发现新的可行的蛋白质组生物标志物候选人在卵巢癌,乳腺癌,结肠癌和肺癌。使用来自心血管健康研究(CHS)的诊断前肺癌样本,我们发现了30种蛋白质组学,糖组学或自身抗体生物标志物,这些生物标志物在随后诊断为肺癌的人群中显著增加(p<0.002)。在这里,我们建议使用来自297名肺结节阳性受试者的血浆样本,这些受试者已经通过CT进行了筛查,并且具有已知的癌症/结节状态(147名是癌症),以测试这30种标志物,并可能发现其他候选者。然后,我们将联合收割机将这些数据与CT成像参数和临床数据相结合,以创建一个风险预测模型,我们将在类似规模的前瞻性收集的队列中进行测试。我们的具体目标是:(1)测试推定的蛋白质组学和糖组学生物标志物识别恶性肺结节的能力。(2)确定血浆中存在的自身抗体是否是肿瘤衍生的,并评估其用于检测癌性结节的效用。(3)对混合血浆生物标志物进行多变量分析,以区分CT胸部成像上识别的恶性和良性结节。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
A McGarry Houghton其他文献
A McGarry Houghton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('A McGarry Houghton', 18)}}的其他基金
Neutrophil derived proteinases abolish the IFNG signature in NSCLC
中性粒细胞衍生的蛋白酶消除 NSCLC 中的 IFNG 特征
- 批准号:
10717448 - 财政年份:2023
- 资助金额:
$ 51.64万 - 项目类别:
Anxa2 drives the function of immune suppressive neutrophils in lung cancer
Anxa2 驱动肺癌中免疫抑制性中性粒细胞的功能
- 批准号:
10310981 - 财政年份:2021
- 资助金额:
$ 51.64万 - 项目类别:
A Quantitative PET/CT Research Resource for Co-Clinical Imaging of Lung Cancer Therapies
用于肺癌治疗联合临床成像的定量 PET/CT 研究资源
- 批准号:
10301566 - 财政年份:2021
- 资助金额:
$ 51.64万 - 项目类别:
A Quantitative PET/CT Research Resource for Co-Clinical Imaging of Lung Cancer Therapies
用于肺癌治疗联合临床成像的定量 PET/CT 研究资源
- 批准号:
10700944 - 财政年份:2021
- 资助金额:
$ 51.64万 - 项目类别:
Liquid biopsy of the lung to profile lung cancer
肺部液体活检以分析肺癌
- 批准号:
10053675 - 财政年份:2020
- 资助金额:
$ 51.64万 - 项目类别:
Liquid biopsy of the lung to profile lung cancer
肺部液体活检以分析肺癌
- 批准号:
10259860 - 财政年份:2020
- 资助金额:
$ 51.64万 - 项目类别:
Liquid biopsy of the lung to profile lung cancer
肺部液体活检以分析肺癌
- 批准号:
10472743 - 财政年份:2020
- 资助金额:
$ 51.64万 - 项目类别:
Liquid biopsy of the lung to profile lung cancer
肺部液体活检以分析肺癌
- 批准号:
10601449 - 财政年份:2020
- 资助金额:
$ 51.64万 - 项目类别:
Project 1: Targeting the Neutrophil Lineage To Enhance Immune Checkpoint Inhibitor Efficacy in NSCLC
项目1:靶向中性粒细胞谱系以增强非小细胞肺癌中免疫检查点抑制剂的功效
- 批准号:
10174872 - 财政年份:2019
- 资助金额:
$ 51.64万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 51.64万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 51.64万 - 项目类别:
Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 51.64万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 51.64万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 51.64万 - 项目类别:
Fellowship
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
- 批准号:
24K13490 - 财政年份:2024
- 资助金额:
$ 51.64万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
- 批准号:
EP/Z00022X/1 - 财政年份:2024
- 资助金额:
$ 51.64万 - 项目类别:
Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
- 批准号:
MR/Y003365/1 - 财政年份:2024
- 资助金额:
$ 51.64万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 51.64万 - 项目类别:
Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
- 批准号:
AH/Y007549/1 - 财政年份:2024
- 资助金额:
$ 51.64万 - 项目类别:
Research Grant